Zhejiang Orient Gene Biotech Co., Ltd (SHA:688298)
22.26
+0.08 (0.36%)
Apr 30, 2026, 1:54 PM CST
SHA:688298 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2,450 | 3,081 | 4,165 | 6,597 | 6,098 |
Short-Term Investments | - | - | - | - | 31.15 |
Trading Asset Securities | 122.59 | 207.58 | 1,052 | 1,161 | 168.07 |
Cash & Short-Term Investments | 2,572 | 3,289 | 5,217 | 7,758 | 6,297 |
Cash Growth | -21.79% | -36.95% | -32.75% | 23.19% | 181.43% |
Accounts Receivable | 213.67 | 230.17 | 207.74 | 309.36 | 1,184 |
Other Receivables | 12.79 | 19.12 | 20.7 | 73.13 | 53.96 |
Receivables | 226.46 | 249.28 | 228.44 | 382.49 | 1,238 |
Inventory | 309.86 | 308.96 | 346.78 | 431.92 | 470.56 |
Other Current Assets | 147.62 | 131.45 | 104.01 | 175.42 | 120.06 |
Total Current Assets | 3,256 | 3,979 | 5,896 | 8,747 | 8,126 |
Property, Plant & Equipment | 2,645 | 2,741 | 2,261 | 1,074 | 481.34 |
Long-Term Investments | 47.85 | 50.27 | 52.35 | 35.59 | 25.45 |
Goodwill | - | - | - | - | 15.41 |
Other Intangible Assets | 883.88 | 690.91 | 478.81 | 481.24 | 111.48 |
Long-Term Deferred Tax Assets | 256.12 | 268.47 | 218.26 | 193.23 | 69.68 |
Long-Term Deferred Charges | 42.12 | 59.71 | 61.05 | 36.32 | 7.37 |
Other Long-Term Assets | 8.13 | 305.85 | 28.05 | 135.63 | 139.81 |
Total Assets | 7,139 | 8,095 | 8,996 | 10,704 | 8,977 |
Accounts Payable | 481.4 | 515.49 | 600.49 | 1,580 | 1,174 |
Accrued Expenses | 65.26 | 72.03 | 68.45 | 218.81 | 175.55 |
Short-Term Debt | 130.55 | 116.78 | 198.22 | - | - |
Current Portion of Long-Term Debt | 11.12 | 300.22 | 50.3 | - | - |
Current Portion of Leases | - | 24.6 | 15.86 | 3.55 | 5.84 |
Current Income Taxes Payable | 12.18 | 3.41 | 3.77 | 17.67 | 606.85 |
Current Unearned Revenue | 37.52 | 30.99 | 34.77 | 339.14 | 71.19 |
Other Current Liabilities | 93.82 | 140.29 | 113.93 | 119.24 | 25.4 |
Total Current Liabilities | 831.86 | 1,204 | 1,086 | 2,278 | 2,059 |
Long-Term Debt | 158.99 | - | 300 | 50 | - |
Long-Term Leases | 25.3 | 47.17 | 43.96 | 28.65 | 12.65 |
Long-Term Unearned Revenue | 26.06 | 34.48 | 10.75 | 17.46 | 17.01 |
Long-Term Deferred Tax Liabilities | 0.04 | 0.23 | 0.04 | 2.76 | - |
Other Long-Term Liabilities | 11.02 | 17.47 | 5.7 | 3.39 | - |
Total Liabilities | 1,053 | 1,303 | 1,446 | 2,381 | 2,088 |
Common Stock | 201.6 | 201.6 | 201.6 | 168 | 120 |
Additional Paid-In Capital | 397.89 | 397.89 | 395.42 | 436.32 | 549.21 |
Retained Earnings | 5,694 | 6,268 | 6,797 | 7,530 | 6,201 |
Treasury Stock | -326.94 | -276.95 | - | - | - |
Comprehensive Income & Other | 26.12 | 54.9 | 42.37 | 28.27 | -12.72 |
Total Common Equity | 5,993 | 6,645 | 7,436 | 8,163 | 6,857 |
Minority Interest | 92.96 | 146.34 | 113.66 | 160.15 | 31.62 |
Shareholders' Equity | 6,086 | 6,791 | 7,550 | 8,323 | 6,889 |
Total Liabilities & Equity | 7,139 | 8,095 | 8,996 | 10,704 | 8,977 |
Total Debt | 325.96 | 488.76 | 608.33 | 82.2 | 18.49 |
Net Cash (Debt) | 2,246 | 2,800 | 4,609 | 7,675 | 6,279 |
Net Cash Growth | -19.78% | -39.24% | -39.95% | 22.24% | 180.61% |
Net Cash Per Share | 11.67 | 14.24 | 22.84 | 38.08 | 31.14 |
Filing Date Shares Outstanding | 190.02 | 193.2 | 201.6 | 201.6 | 201.6 |
Total Common Shares Outstanding | 190.02 | 193.2 | 201.6 | 201.6 | 201.6 |
Working Capital | 2,424 | 2,775 | 4,810 | 6,469 | 6,068 |
Book Value Per Share | 31.54 | 34.40 | 36.89 | 40.49 | 34.01 |
Tangible Book Value | 5,109 | 5,954 | 6,957 | 7,682 | 6,730 |
Tangible Book Value Per Share | 26.89 | 30.82 | 34.51 | 38.10 | 33.38 |
Buildings | - | 1,465 | 1,296 | 586.6 | 243.61 |
Machinery | - | 437.85 | 360.52 | 262.56 | 177.03 |
Construction In Progress | - | 1,134 | 796.48 | 369.99 | 112.45 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.